Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment
The mechanisms underlying variable efficacy of Relugolix-Combination Therapy (REL-CT) in mitigating unexplained pelvic pain will be evaluated with uterine imaging techniques and quantitative sensory testing.
- EligibilityCriteria: Inclusion Criteria  Idiopathic pelvic pain (40 participants):  Self-report an average non-menstrual pelvic pain rating of ≥ 2/10 (on a 0 to 10 Numeric Rating Scale) over the past 6 months. Not have received a prior diagnosis attributed to a secondary cause (e.g., leiomyoma, endometriosis).  Endometriosis (20 participants)  Self-report an average non-menstrual pelvic pain rating of ≥ 2/10 (on a 0 to 10 Numeric Rating Scale) over the past Previously confirmed surgical diagnosis of stage III-IV endometriosis, indicating potential remission.  Exclusion Criteria:  History of blood clots, Allergies to REL-CT ingredients Diabetes Migraines Osteoporosis Vascular disease Hormone-sensitive cancers Smoking. Missing limbs Paralysis, Conditions associated with irregular menses Congenital conditions affecting reproductive function Intrauterine device use Pelvic inflammatory conditions Active genitourinary infections, Inability to read or comprehend the informed consent document written in English History of metallic implants, history of metallic injury, any condition precluding investigation with MRI BMI exceeding 40 Uncontrolled thyroid dysfunction Adrenal dysfunction Renal disorders Liver disorders Coagulopathy, Gastrointestinal conditions or surgeries that may affect absorption - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - MaximumAge: 35 Years - StdAgeList: Adult